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ABSTRACT 
Objective: The objective of the present study was to evaluate the acute and sub-chronic (90 d; repeated dose) toxicity of Withania somnifera 
(ashwagandha) extract in rats. 
Methods: The acute toxicity was evaluated as per OECD (Organisation for Economic Co-operation and Development) guidelines 423. Purified 
ashwagandha extract (PAE) was fed at 2000 mg/kg body weight (bw) to overnight fasted female rats. The animals were observed daily for clinical 
signs of abnormality/mortality. After 14 d, animals were sacrificed and gross pathological changes were recorded. Sub-chronic toxicity of PAE was 
studied by feeding the extract at 100, 500 and 1000 mg/kg bw daily to rats as per OECD guidelines 408. After 90 d feeding, heamatological and 
biochemical parameters of treated rats were compared with control animals. Histopathology of all the major organs was also studied. 
Results: In the acute toxicity study, no mortality or clinical signs of toxicity were observed in any of the animals at maximum recommended dose level 
of 2000 mg/kg bw; therefore the LD50 is>2000 mg/kg bw in rats. The repeated administration of PAE for 90 d in rats at the maximum dose level of 
1000 mg/kg bw did not induce any observable toxic effects, when compared to its corresponding control animals. The hematology and biochemistry 
profile of treated rats was similar to control animals and difference was non-significant (p>0.05). The histopathology of major organs of all the control 
and treated animals was normal. In this study the NOAEL (No Observed Adverse Effect Level) was calculated as 1000 mg/kg bw daily for rats.  
Conclusion: The present study clearly indicates that PAE does not have any toxic effects in animals at the dose evaluated as evidenced by acute and 
sub chronic toxicity studies in rats. 
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Withania somnifera (ashwagandha) belongs to family Solanaceae is 
commonly known as “Indian Ginseng” or “Winter Cherry”. The literal 
meaning of the word “Ashwagandha” is “smell of horse”. The fresh 
roots of the herb emit the smell of horse and there is a commonly 
held belief that a person consuming the herb may develop the 
strength and vitality similar to that of a horse [1]. Ashwagandha has 
been used as a ‘Rasayana’ and the roots of ashwagandha are 
regarded as adaptogenic, tonic, aphrodisiac, anti-inflammatory, 
diuretic, anthelmintic, astringent, thermogenic and stimulant [2]. 
The ethanol extract obtained from the leaves of field grown 
ashwagandha has been reported for antioxidant potential [3]. The 
extract obtained from roots has also been found to have free radicals 
scavenging activity [4]. The anti-microbial activity of ashwagandha 
has been reported against many pathogenic bacterial strains [5]. 
The major phytochemical constituents reported from ashwagandha 
are alkaloids (isopelletierine, anaferine, cuscohygrine, anahygrine, 
tropine, somnine, sominiferine, withanine etc), steroidal lactones 
(withanolides, withaferins), saponins containing an additional acyl 
group (sitoindoside VII and VIII), withanolides with a glucose at 
carbon 27 also known as glycol-withanolides (sitoindoside IX and X) 
and amino acids like aspartic acid, proline, tyrosine, alanine, glycine 
etc [6]. Many herbal supplements are commercially available 
containing 1-3% alkaloids and small amount of withaferine. The 
pharmacological activity of such products has been claimed as due 
to presence of alkaloids and/or withaferine. The European Food 
Safety Authority (EFSA) has categorized some of the alkaloids of 
ashwagandha as toxic and harmful [7]. These include anaferine, 
anahygrine, withanine, sominiferine, somnine, tropine etc. Apart 
from alkaloids, withaferine A has also been categorized as cytotoxic 
lactone by EFSA [7]. The aim of the present study, therefore, was to 
assess the toxicity of a purified ashwagandha extract as per OECD 
(Organisation for Economic Co-operation and Development) 
guidelines to support its safety for human use. 
MATERIALS AND METHODS 
Chemicals and animals  
Purified ashwagandha extract (PAE) manufactured by Arjuna Natural 
Ltd., Aluva, Kerala, India was used as a test sample for toxicity study. 
The extract is standardized to contain 35% glycowithanolides and less 
than 1% alkaloids. Reference standards for glycowithanolides 
(Withanoside IV and Withanoside V) and aglycowithanolides 
(Withaferin A, Withanolide A and 12-Deoxy-withastramonolide) were 
purchased from Chromadex, CA, USA. Eight weeks old Sprague Dawley 
rats weighing 160-180 g were maintained at 24±2 °C with 55-70 % 
relative humidity and lighting was controlled to give 12 h artificial 
light (6 am-6 pm) each day. Filtered drinking water (Aquaguard) and 
pellet feed manufactured by M/s. Kerala feeds, Thrissur, India was 
provided ad libitum. The study was approved by Institutional Animals 
Ethics Committee of Arjuna Natural Ltd., Kochi, Kerala, India 
(1524/PO/RcBi/S/11/CPCSEA). 
Phytochemical screening of the extract 
The PAE was subjected to qualitative chemical tests for the presence 
of various categories of phytoconstituents. Quantification of 
phenolics [8], flavonoids [9], tannins [10], triterpenoids [11], 
alkaloids [12], saponins [13], carbohydrates and protein [14] was 
done by existing standard methods. 
Quantification of withanolides was done by high performance liquid 
chromatography (HPLC). The PAE was accurately weighed (125 mg) 
and transferred into a 25 ml standard flask and made up to a 25 ml 
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solution with 50% aqueous methanol. Standard solutions were 
prepared by weighing accurately 5 mg standard into a 5 ml standard 
flask and made up to a 5 ml with methanol. From these stock solutions, 
200 µl was transferred into 10 ml standard flask and made up to 10 ml 
with methanol. All the solutions were filtered through 0.2 μm filter 
before injection. HPLC was performed on reverse phase C18 column 
(250×4.6 mm; Shimadzu Co., Japan) using 0.01M anhydrous potassium 
dihydrogen orthophosphate (mobile phase A) and acetonitrile (mobile 
phase B) as the mobile phase and UV detection at 227 nm. The flow 
rate was 1 ml/min and run time was 40 min. The concentration 
gradient for mobile phase B was 5-45% (18 min), 45-80% (7 min), 
hold 80% (3 min), 80-5% (2 min), hold 5% (10 min). 
Acute toxicity study in rats 
This study was performed in accordance with the OECD guideline 
for the testing of chemicals, “Acute Oral Toxicity Study (Acute Toxic 
Class Method)”, Guideline No. 423, adopted on December 17, 2001. 
Six female rats weighing 160-180 g were used in this study. The 
study was divided into two steps and the animals were acclimatized 
for 7 d before the commencement of each step. The animals were 
fasted overnight before and four hours after dosing. Taking three 
rats in the first step, a limit test was performed. The test substance 
(PAE dissolved in distilled water) was administered orally at the 
dose level of 2000 mg/kg body weight (bw) with the help of a 
stainless steel cannula attached with syringe in the first step. No 
mortality or toxic signs and symptoms were observed in any of the 
animals at the first step, hence to confirm the findings of first step 
the next step was performed by taking three more female rats, 
which were administered the same dose of 2000 mg/kg bw. 
The treated rats were observed for clinical signs of 
abnormality/mortality five times on day 1 (day of administration) 
i.e., at 30 min and four times at hourly (post-administration) 
intervals and thereafter once daily for a total of 14 d. The body 
weights of rats were recorded on day 1, day 7 and day 14. No 
mortality or treatment related toxic signs and symptoms were 
observed in the animals at both the steps. As no toxic signs were 
noted, no further testing was required. After 14 d, animals were 
sacrificed and gross pathological changes were recorded. 
Sub-chronic (90 d repeated dose) toxicity study 
This study was conducted as per OECD guidelines for testing of 
chemicals (No.408). One hundred rats (50 males/50 females) were 
divided into four groups of 20 animals (10 males and 10 females) in 
each and two groups (satellite/recovery groups) of 10 animals (5 
males and 5 females) in each group. The animals were acclimatized 
for seven days before the commencement of dosing. Three groups of 
20 rats each (10 male and 10 female) were administered with PAE 
orally at the dosage levels of 100 mg/kg bw (low dose; LD), 500 
mg/kg bw (medium dose; MD) and 1000 mg/kg bw (high dose; HD) 
respectively for seven days a week for 90 d with the help of cannula 
attached with the syringe. Similarly, fourth group of 20 rats (10 male 
and 10 female rats) were orally administered with distilled water 
only (vehicle) for 90 d and was designated as control group. 
Two additional satellite (recovery) groups of 10 rats (5 male and 5 
female) each were also kept and designated as ‘Satellite control’ and 
‘Satellite high dose’ and were administered with distilled water 
(vehicle) and test substance (PAE, 1000 mg/kg bw) respectively daily 
for 90 d. After terminal sacrifice of the test and control group animals, 
both recovery group animals (satellite control and satellite high dose) 
were kept under observation for an additional one month, to check the 
reversibility, persistence or delayed toxic effect, if any. The animals 
were observed daily for behavior, appearance and toxicological signs 
and symptoms. Blood was collected from retro orbital sinus from all 
the animals before terminal sacrifice for detailed hematological and 
biochemical evaluation. Criteria used to evaluate compound related 
effects included; appearance, behavior, morbidity, mortality, body 
weights, feed consumption, hematological and biochemical analysis, 
organ weights, necropsy and histopathology. 
Statistical analysis 
Using Graph Pad Prism software the data was analysed by one-way 
analyses of variance (ANOVA). Following ANOVA, Dunnett’s pair-
wise comparison of means of treated groups with control group 
mean was carried out individually. The data is presented as the 
mean±SEM (standard error of mean) and p value<0.05 was 
considered as significant. 
RESULTS  
Phytochemical screening 
The PAE was found to be rich in triterpinoids, saponins and 
carbohydrates. The percentage of withanolide glycosides 
(glycowithanolides) was 35% whereas the percentage of alkaloids in 
PAE was below 1%.  
Acute toxicity study in rats 
No clinical sign of toxicity was observed in any of the treated rat at 
the dose level of 2000 mg/kg bw. No mortality was observed in the 
animals at step I and step II administered with the PAE at 2000 
mg/kg bw. Individual body weights were recorded prior to oral 
administration (day 1) and on days 7 and 14 following oral 
administration. The gain in body weights was normal in all the rats 
(table 1). All animals were sacrificed at the end of the study and they 
did not reveal any abnormality of pathological significance. External 
examination of terminally sacrificed rats also did not reveal any 
abnormality of pathological significance. Based on these findings of 
the acute oral toxicity (Acute Toxic Class Method) of the PAE in rats, 
the LD50 of the extract may be classified as GHS (Globally 
Harmonized System) category 5 (LD50
 
>2000 mg/kg bw) as per 
OECD Guideline No. 423, December 2001. 
Table 1: Body weight, body weight changes and pre-terminal deaths in acute toxicity study 
Dose (mg/kg b.w.) Rat No. Sex Body weight (g) No. dead/No. tested 
Day 1 Day 7 Day 7–Day 1 Day 14 Day 14–Day 1 
2000 1 Female 161 172 11 178 17 0/6 
 2 Female 164 170 6 176 12 
3 Female 160 167 7 173 13 
4 Female 159 169 10 174 15 
5 Female 178 184 6 190 12 
6 Female 172 177 5 191 19 
 
Sub-chronic toxicity study 
No treatment related toxic sign and symptoms were observed in LD, 
MD and HD group animals when compared to their respective 
control counter parts. Body weight gain and feed consumption of all 
the treatment group animals was comparable to their control 
counterparts (data not shown). 
There were no variations in the hematological parameters of 
animals of LD, MD and HD groups when compared to the control 
group animals (table 2-3). Similarly, the biochemical parameters of 
animals of all the treatment groups i.e. LD, MD and HD were 
comparable to the biochemical parameters of the control group 
animals at the terminal sacrifice (table 4-5). 
None of the animals died during the study in any of the treated 
groups as well as the control group. After completion of dosing 
period of 90 d (120 d for recovery groups) all the animals 
(treatment and control) were sacrificed and were examined for 
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gross pathological findings. Organ weights of animals of all 
treatment groups were comparable to their respective control 
counter parts (data not shown). There were no significant 
histopathological changes in the animals of LD, MD and HD group 
when compared to their control counterparts (fig. 1). 
In this study, the repeated administration of PAE for 90 d, by oral 
route, to rats at the highest dosage level of 1000 mg/kg bw did not 
induce any observable toxic effects, when compared to its 
corresponding control group of animals. Therefore, this dose may be 
considered as the No Observed Adverse Effect Level (NOAEL). 
 
Table 2: Heamatological parameters of male rats in sub-chronic (90 d repeated dose) toxicity study 




























































































































































Analysis of variance (ANOVA) was used for statistical analysis. Data are presented as the mean±SEM. P>0.05, compared with the respective control. 
No significant differences were observed between the test and control groups. Hb=Hemoglobin; N=Neutrophils; E=Eosinophils; L=Lymphocytes; 
PCV=Packed Cell Volume (Hematocrit); MCV= Mean Corpuscular Volume; MCH= Mean Corpuscular Hemoglobin; MCHC= Mean Corpuscular 
Hemoglobin Concentration; RDW= Red Blood Cell Distribution Width. 
 















































































































































































Analysis of variance (ANOVA) was used for statistical analysis. Data are presented as the mean±SEM. P>0.05, compared with the respective control. 
No significant differences were observed between the test and control groups. Hb=Hemoglobin; N=Neutrophils; E=Eosinophils; L=Lymphocytes; 
PCV=Packed Cell Volume (Hematocrit); MCV= Mean Corpuscular Volume; MCH= Mean Corpuscular Hemoglobin; MCHC= Mean Corpuscular 
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Analysis of variance (ANOVA) was used for statistical analysis. Data are presented as the mean±SEM. P>0.05, compared with the respective control. 
No significant differences were observed between the test and control groups. CHO=Cholesterol; TG=Triglycerides; ALKP=Alkaline phosphatase; T. 
Bil=Total Bilirubin; T. Pro=Total Protein; Alb=Albumin; Glo=Globulin; SGOT=Serum glutamic oxaloacetic transaminase; SGPT=Serum glutamic 
pyruvic transaminase; Cre=Creatinine; FBS=Fasting Blood Sugar 
 
 
Fig. 1: Histopathological sections of major organs in 90 d repeated dose toxicity study 
Table 5: Biochemical parameters of female rats in in sub-chronic (90 d repeated dose) toxicity study 
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Analysis of variance (ANOVA) was used for statistical analysis. Data are presented as the mean±SEM. P>0.05, compared with the respective control. 
No significant differences were observed between the test and control groups. CHO=Cholesterol; TG=Triglycerides; ALKP=Alkaline phosphatase; T. 
Bil=Total Bilirubin; T. Pro=Total Protein; Alb=Albumin; Glo=Globulin; SGOT=Serum glutamic oxaloacetic transaminase; SGPT=Serum glutamic 
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DISCUSSION 
Ashwagandha has a number of benefits and pharmacological activities. 
Root powder of ashwagandha has been used in the Ayurvedic system 
of medicine since ancient times. The extracts of ashwagandha are not 
mentioned in Ayurveda, and the content of phytochemicals in such 
extracts is higher compared to raw powder. Animal toxicity studies 
with such extracts may help to establish safe doses in humans. A sub-
acute toxicity study with hydroalcoholic extract of ashwagandha 
showed no evidence of toxic effect or mortality in Wistar rats [15]. 
Similarly, hydro alcoholic extract of ashwagandha was found to be safe 
in a sub-acute toxicity study involving rats and mice [16]. However the 
content of glycowithanolides and alkaloids in these hydro alcoholic 
extracts are not reported. 
Owing to the presence of some toxic alkaloids in the root powder and 
crude extracts, safety of the commercially available extracts has been 
raised [7]. In few cases, it has been reported that ingestion of 
ashwagandha might cause stomach upset, diarrhea, and vomiting [2]. 
The alkaloid rich part of commercial ashwagandha extract was found 
to be toxic in a zebrafish embryo acute toxicity test as per OECD 
guideline 236 whereas detoxified ashwagandha extract (rich in 
glycowithanolides and containing very less alkaloids) was found to be 
non-toxic under the conditions of the study (under publication). 
In the assessment and evaluation of the toxic characteristics of a test 
substance, determination of acute oral toxicity study in small animals 
(mice/rats) is usually an initial step. Results of acute toxicity obtained in 
this study clearly indicate that the PAE is acutely safe up to 2000 mg/kg 
bw in rats. The LD50 for rats was found to be>2000 mg/kg bw which 
suggests that it is extremely safe. The 90 d repeated dose toxicity study 
in rats further supports the lack of toxicity of test sample as the repeated 
administration of PAE for 90 d to rats at the dosage level of 1000 mg/kg 
bw did not induce any observable toxic effects, when compared to its 
corresponding control group of animals. The biochemical and 
hematological parameters were normal. The histopathological 
observations of all the major organs were also normal. Converting rat 
dose to human equivalent dose, the 1000 mg/kg bw in rats corresponds 
to about 11 g daily in human [17].  
CONCLUSION 
The present study clearly indicates that PAE has no 
adverse/toxic effects in animal models at tested dosages as per 
OECD guidelines. It can be concluded that PAE is non-toxic at 
tested dose levels as evidenced by acute and repeated dose 
toxicity studies. 
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